March 2026 in “Jurnal Pharmascience” This study found that isorhamnetin, a compound from the Rampai plant, showed a lower affinity energy in molecular docking tests compared to Minoxidil, indicating potential as an androgen receptor antagonist for alopecia therapy in silico, with favorable pharmacokinetic characteristics in ADME-Tox predictions.
January 2024 in “Journal of Applied Pharmaceutical Science” This study identified procyanidin B2 and leucopelargonidin from Saraca asoca as potential inhibitors in PCOS by showing high binding energy scores against key enzymes involved in estrogen and testosterone biosynthesis.
November 2023 in “International journal of biology, pharmacy and allied sciences” This review highlights scientific information about the medicinal uses and phytochemistry of Musa paradisiaca plant parts, which are traditionally used in human medicine to treat conditions such as diabetes, diarrhoea, hypertension, and ulcers, and exhibit various pharmacological activities including antidiabetic, antioxidant, and wound healing effects.
May 2024 in “EAS Journal of Pharmacy and Pharmacology” In this study, researchers used molecular docking to show that compounds from pomegranate peels, such as apigenin, luteolin, and taxifolin, effectively inhibit the enzyme 5α-reductase, suggesting potential anti-alopecic properties.
7 citations
,
April 2021 in “Journal of advanced pharmaceutical technology & research” This study reported that compound 16 (olean-12-en-3beta-ol, cinnamate) from Merremia peltata showed potential as an androgen receptor antagonist, suggesting it may benefit alopecia treatment based on molecular docking and ADME-Tox predictions.